CLNN - Clene Inc

6.15
-0.420   -6.829%

Share volume: 91,934
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$6.57
-0.42
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
52%
Profitability 35%
Dept financing 43%
Liquidity 73%
Performance 65%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
7.33%
3 Months
21.30%
6 Months
-26.26%
1 Year
94.01%
2 Year
1,724.93%
Key data
Stock price
$6.15
P/E Ratio 
N/A
DAY RANGE
$6.11 - $6.64
EPS 
-$3.84
52 WEEK RANGE
$2.28 - $13.50
52 WEEK CHANGE
$105.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
11.778 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$79,756
AVERAGE 30 VOLUME 
$91,262
Company detail
CEO: Robert D. Etherington
Region: US
Website: clene.com
Employees: 100
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.

Recent news